| Objective: To compare the clinical outcomes between short-course preoperativeradiotherapy（SCRT） and long-course preoperative radiochemotherapy （LCRT）for stage Ⅱ or Ⅲ rectal cancer with Meta-analysis.Methods: Original articles published since the building of the library to December2012were searched in the Pubmed, Ovid, SpringerLink, CNKI and Wanfang data,which compared the clinical outcomes between short-course preoperativeradiotherapy and long-course preoperative radiochemotherapy for stage Ⅱ or Ⅲ rectalcancer. Data were extracted from these trials by2reviewers independently andanalyzed by Rev Man5.2software.Results: According to the criterion,9articles were identified. The analyses show thatthe SCRT group’s T downstage rate is less than LCRT group（OR=0.52,95%CI:0.36-0.75, p=0.0004）, the SCRT group’s pathological complete response rate is lessthan LCRT group（OR=0.08,95%CI：0.03-0.19, p<0.00001）. There was nosignificant difference in the rate of R0resection between the two groups（OR=0.70,95%CI：0.31-1.58, P=0.39）. The SCRT group’s postoperative complication rate ishigher than LCRT group（OR=1.70,95%CI：1.08-2.69, p=0.02）. There was nosignificant difference in the rate of sphincter preservation between the twogroups(OR=1.46,95%CI：0.4-5.31, P=0.57）. There was no significant difference inthe rate of late toxicity between the two groups（OR=0.95,95%CI：0.61-1.49,P=0.82）. There was no significant difference in the3-year overall survival rate between the two groups（HR=1.05,95%CI：0.67-1.65, P=0.83）. There was nosignificant difference in the3-year disease free survival rate between the two groups（HR=1.02,95%CI：0.71-1.46, P=0.93）.Conclusion: In phase Ⅱ/Ⅲ rectal cancer, compared to SCRT, LCRT hasadvantages on T downstage rate, complete response rate and postoperativecomplication rate. There was no significant difference in the rate of late toxicity, R0resection rate sphincter preservation rate,3-year overall survival rate and3-yeardisease free survival rate between the two groups. |
PDF Full Text Request